Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden infections in lung cancer patients

NCT ID NCT02821949

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring procalcitonin (PCT) levels in the blood could help detect infections earlier in people with stage IV non-small cell lung cancer starting chemotherapy. Researchers enrolled 45 patients and took a PCT blood sample before their first chemo session, without telling their doctors the results. They then followed patients for 30 days to see if any developed infections. The goal was to see if PCT could be a more reliable infection marker than the standard CRP test in these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
procalcitonin (PCT) blood test
What this could lead to
If successful, this could provide a simple blood test to help doctors spot infections earlier in advanced lung cancer patients on chemotherapy.
What could go wrong
This is a small, early observational study with only 45 participants. It does not test any treatment, so it cannot directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

45 people

The number who actually took part.

Started

Dec 2014

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients suffering from a stage 4 NSCLC

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with stage IV NSCLC, hospitalized for his first seance of chemotherapy * Medical conditions permitting chemotherapy * Informed consent signed * Patient covered by social insurance Exclusion Criteria: * Patient with small cell lung cancer * Patients with NSCLC stage I, II or III of the Tumor Node Metastasis classification * Patient with stage IV NSCLC, who received prior treatment (radiotherapy, chemotherapy ...) * Patient with infection (on clinical and paraclinical criteria) not compatible with the administration of the first seance of chemotherapy. * Pregnant or breastfeeding women Private Patient freedom or in a position to judicial protection (guardianship)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cells lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non small cells lung cancer

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France